family with sequence similarity 43 member BGenealiases: []
Q-omics provides the consensus-scored FAM43B profile across patient tissues and cancer cell-line models. FAM43B expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, FAM43B is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, FAM43B RNA expression shows 12,489 significant gene co-expression associations, with the highest sampling consensus in PAAD. Together, these results highlight KIRC, and PAAD as cancer lineages where FAM43B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM43B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM43B survival associations across molecular data types. FAM43B RNA expression shows survival associations in the most cancer types (27), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM43B RNA expression–survival associations across cancer types. High FAM43B expression shows unfavorable associations in KIRC, LUSC, MESO, UVM and LGG, but favorable associations in ACC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for FAM43B RNA expression.
This table summarizes FAM43B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for FAM43B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM43B shows lower tumor expression in KIRC, COAD, KICH, THCA and KIRP and higher tumor expression in CHOL. The KIRC box plot shows higher FAM43B RNA expression in normal versus tumor tissue (log2 FC = −1.163, t-test p < 0.001).
This table shows molecular features associated with FAM43B in patient tissues and cancer cell lines. In patient samples, FAM43B shows the broadest associations at the RNA and protein expression levels, with PAAD recurring as the lineage with the largest associated feature set. In cancer cell lines, FAM43B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in LIVER and BLOOD_Leukemia.
